Acalabrutinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Iloprost
Vasodilator · Pulmonary arterial hypertension agent
Also known as Ventavis, synthetic PGI2
VasodilatorPulmonary arterial hypertension agent
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
C
FDA category + note
Top interactionssee all 12 →
- AcalabrutinibSevereDatabaseDDInter
- ApixabanSevereDatabaseDDInter
- ArdeparinSevereDatabaseDDInter
- AvapritinibSevereDatabaseDDInter
Mechanism
Iloprost is a synthetic analog of prostacyclin (PGI2). It acts as a potent vasodilator, particularly in the pulmonary vasculature. Its mechanism of action is similar to prostacyclin, involving agonism of the prostaglandin I receptor (IP receptor), which leads to increased intracellular cyclic AMP and relaxation of vascular smooth muscle.
Indications
Pulmonary arterial hypertensionIdiopathic pulmonary arterial hypertension (PAH)targeting the pulmonary vasculature with less systemic side effectsalternative for epoprostenol in combination therapy for severe PAH (functional class IV)
Dosing
- Adult
- Intermittent inhalation via nebulization: Start at 2.5 mCg/dose. If tolerated, increase dose to 5 mCg/dose at intervals of 6 to 9 times daily (Q2-3 hr while awake).
- Pediatric
- Some recommend 1.25 mCg/dose for infant and small child.
- Hepatic adjustment
- Q3-4 hr may be considered for patients with moderate/severe hepatic impairment.
Pharmacokinetics
Onset
Effects of a single inhalation decline to baseline over 60 to 120 min.
Metabolism
Minor CYP-dependent metabolism
Contraindications
- Use with caution in bleeding disorders
- Use with caution in respiratory diseases
- Use with caution in hypotension
Side effects
Common
Headachenauseacoughflu-like symptomsflushingjaw painhypotensionthroat irritationinsomnia
Serious
- Bronchospasm
- hypotension
- AKI
- pulmonary edema
Pregnancy & lactation
Pregnancy
C
Drug interactions
Apixaban
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Ardeparin
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Avapritinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Betrixaban
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cabozantinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Dalteparin
Severe
Database
Clinical effect not specified
Source: DDInter
Danaparoid
Severe
Database
Clinical effect not specified
Source: DDInter
Dasatinib
Severe
Database
Clinical effect not specified
Source: DDInter
Deferasirox
Severe
Database
Clinical effect not specified
Source: DDInter
Drotrecogin Alfa
Severe
Database
Clinical effect not specified
Source: DDInter
Edoxaban
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Other Vasodilator drugs
Ask House about Iloprost
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung, BNF, Harriet Lane·Verified: 2026-05-10 · House clinical team